Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Eczacıbaşı Group.

    Client Virtual Booth

    ECZACıBAşı GROUP

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Eczacıbaşı Group
    turkeypng-1602828403png-1622460951png-1622462103 Flag
    Country
    Country
    Turkey
    Address
    Address
    Kanyon Office Büyükdere Caddesi 185 Levent 34394
    Telephone
    Telephone
    0 212 371 70 00
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.eczacibasi.com.tr/tr/Yoneticiler/SedatBirol3
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Monrol and FutureChem Announced a Clinical Supply Partnership

    Details:

    177Lu-FC705 belongs to the 2nd generation of albumin binders introduced drugs. Its hydrophilicity is higher than that of other compounds, and has low nonspecific binding.


    Lead Product(s): [177Lu]Ludotadipep

    Therapeutic Area: Oncology Product Name: 177Lu-FC705

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: FutureChem

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership November 18, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PharmaMar Signs a New Licensing and Commercialization Agreement With Eczacibasi for Lurbinectedin in Turkey

    Details:

    Eczacıbaşı will pursue the marketing authorization in Turkey and will have the right to commercialize the Zepzelca (Lurbinectedin), on an exclusive basis, upon approval. Lurbinectedin was granted accelerated approval by FDA for relapsed metastatic Small Cell Lung Cancer.


    Lead Product(s): Lurbinectedin

    Therapeutic Area: Oncology Product Name: Zepzelca

    Highest Development Status: ApprovedProduct Type: Small molecule

    Recipient: PharmaMar

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement December 22, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search